BresaGen signs two new contracts
Tuesday, 02 August, 2005
Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
The first is with Irish based Opsona Therapeutics, which will use BresaGen to progress process development of its pre-clinical immunomodulator, OPN-201. The second contract is with US firm Pepgen Corporation, which first partnered with BresaGen in 2004, to develop a process for Pepgen to produce a novel interferon alpha analog, Neoferon.
Under the contract, BresaGen will further develop the E. coli-based process and produce GLP recombinant protein.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...